REPORT HIGHLIGHT
Preimplantation Genetic Testing Market size was valued at USD 807.85 Million in 2023, expanding at a CAGR of 7.2% from 2024 to 2032.
Preimplantation genetic testing (PGT) permits the transfer of genetically normal embryos while identifying aberrant embryos. It reduces the trauma associated with premature miscarriages and several unsuccessful in vitro fertilization (IVF) cycles. Children are also shielded against hereditary monogenic diseases by it.
Preimplantation Genetic Testing Market- Market Dynamics
Growing awareness of genetic testing to propel market demand
Over the projection period, there is development potential for this vertical due to increased knowledge of genetic procedures for chromosomal abnormality identification and embryo screening for successful IVF. For instance, in April 2023, The Prelude Network and The HelpCureHD Foundation started the More Than Infertility campaign to educate and create awareness about IVF with preimplantation genetic testing (PGT) to eliminate genetic abnormalities such as Huntington's disease in babies.
Preimplantation Genetic Testing Market- Key Insights
- As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.2% over the forecast period (2024-2032)
- Based on procedure segmentation, the PGD segment is expected to capture a significant market share during the forecast period
- Based on end-use segmentation, the Hospitals segment is expected to grow at a significant rate over the forecast period
- Based on region, North America was the leading revenue generator in 2023
Preimplantation Genetic Testing Market- Segmentation Analysis:
- The Global Preimplantation Genetic Testing Market is segmented based on Procedure, Product, Technology, Application, End-Use, and Region.
- Based on the procedure, the market is segmented into PGD and PGS. The PGD segment is expected to capture a significant market share during the forecast period. The primary driver of the segment's growth is rising consumer and healthcare professional knowledge of genetic testing for certain gene mutations. Growth is fueled by the increasing prevalence of translocation instances and single gene illnesses as well as the efficient use of NGS technology for genetic testing by market players. Preimplantation genetic diagnostic (PGD) services enable the testing of an embryo to ascertain if it possesses a certain gene mutation, hence lowering the frequency of genetic illnesses in newborns.
- Based on the end-use, the global industry is bifurcated into Diagnostic Centers, Hospitals, Fertility Centers and Research Centers and Academic Labs. The Hospitals segment is expected to grow at a significant rate over the forecast period. The expansion of the category may be attributed to many causes, including a rise in patient volume, enhanced healthcare facilities, and the existence of both public and private institutions providing in vitro fertilization services. Due to the extremely advanced technology that hospitals offer, most couples seeking fertility therapy travel there for additional therapies. Furthermore, an increase in testing rates in hospital settings is anticipated due to the growth in research conducted there. Furthermore, it is anticipated that in the upcoming years, the hospital category will develop at the quickest rate.
Preimplantation Genetic Testing Market- Geographical Insights
Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to dominate the market during the forecast period. The dominance is due to an increasing amount of cases of chromosomal abnormalities leading to numerous genetic illnesses. The rising consumer awareness in this area as well as the existence of major market players are other factors propelling the market's expansion. Research released in April 2021 by the Centers for Disease Control and Prevention (CDC) estimated that around 6,000 kids born in the United States each year have Down syndrome. Similarly, in February 2021 article from the Province of British Columbia, Canada, said that one in every 750 live births in Canada had Down syndrome. Furthermore, statistics from the Facets Journal in November 2021 showed that one in twelve Canadians suffer from uncommon illnesses, with the majority of them having underlying genetic origins. The market in the area was driven by the significant demand that followed early diagnosis to find the genetic flaws in embryos.
Preimplantation Genetic Testing Market- Competitive Landscape:
Major firms are implementing tactics including joint ventures, acquisitions, and the introduction of new products to bolster their position in other local markets. This may result in more effective product development, increased market penetration, or operational efficiency.
Recent Developments:
In October 2022, with preimplantation genetic testing, HelpCureHD and Genomic Prediction are collaborating to assist couples who may be at risk of developing Huntington's disease (HD). Currently, there is no effective treatment for HD, a genetic brain disease.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL PREIMPLANTATION GENETIC TESTING MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Quest Diagnostics Incorporated
- Thermo Fisher Scientific Inc.
- Laboratory Corporation of America Holdings
GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE- MARKET ANALYSIS, 2019 - 2032
GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT- MARKET ANALYSIS, 2019 - 2032
- Instruments
- Software
- Reagents and Consumables
GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY- MARKET ANALYSIS, 2019 - 2032
- Fluorescent In-Situ Hybridization (FISH)
- Next Generation Sequencing (NGS)
- Polymerase Chain Reaction (PCR)
- Others
GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032
- Chromosomal Abnormalities
- Aneuploidy Screening
- Embryo Testing
- X-linked Diseases
- HLA Typing
- Others
GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, BY END-USE- MARKET ANALYSIS, 2019 - 2032
- Diagnostic Centers
- Hospitals
- Fertility Centers
- Research Centers and Academic Labs
GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
- North America
- The U.S.
- Canada
- Europe
- Germany
- France
- Italy
- Spain
- United Kingdom
- Russia
- Netherlands
- Sweden
- Poland
- Rest of Europe
- Asia Pacific
- India
- China
- South Korea
- Japan
- Australia
- Thailand
- Indonesia
- Philippines
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA